Clinical trial NCT06551324: A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Official title: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Keywords: Prostate cancer
Enhancer of zeste homolog 2
castrate resistant prostate cancer
Hormone resistant
Metastatic hormone resistant prostate cancer
Metastatic castrate resistant prostate cancer
PF-06821497
Enzalutamide
Docetaxel
Advanced prostate cancer
Efficacy
Safety
Open-label
Relapsed
refractory
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2024-08-13
Enrollment: 600
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.

The primary objective of this clinical trial is to assess the radiographic progression free survival (rPFS) of the combination of PF-06821497 plus enzalutamide versus physician's choice of enzalutamide or docetaxel.


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
* Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
* Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first line mCRPC setting is required.
* Eastern Cooperate Oncology Group (ECOG) performance status 0 - 2, with life expectancy of at least 6 months as assessed by the investigator.

Exclusion Criteria:

* Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may make the participant inappropriate for the study.
* Know history of active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery.
* Clinically significant cardiovascular disease.
* Known or suspected brain metastasis or active leptomeningeal disease or clinically significant history of seizure.
* Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy (i.e. 177Lu-PSMA-617, radium 223), androgen receptor signaling inhibitors (ARSi) including enzalutamide, apalutamide, darolutamide, poly ADP-ribose polymerase (PARP) monotherapy or other systemic anti-cancer treatment, with the following exceptions:

  1. Treatment with first-generation antiandrogen agents, if discontinued prior to first dose of study intervention.
  2. Docetaxel treatment is allowed for mCSPC, as long as no signs of failure, or disease progression occurred during treatment or within 3 months of treatment completion.
* Previous administration with an investigational product within 30 days or 5 half-lives preceding the first dose of study intervention (whichever is shorter).
* Inadequate organ function.

Primary outcomes:
measure: Radiographic Progression Free Survival (rPFS) assessed by blinded independent central review (BICR) per RECIST v1.1 and Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
timeFrame: Randomization up to approximately 2 years.
Secondary outcomes:
measure: Overall survival (OS)
timeFrame: Randomization up to approximately 4.5 years.
measure: Objective Response (ORR)
timeFrame: Randomization up to approximately 2 years.
measure: Duration of Response (DoR) in measurable soft tissue disease
timeFrame: Randomization up to approximately 2 years.
measure: Time to prostate specific antigen (PSA) progression.
timeFrame: Randomization up to approximately 2 years.
measure: Time to initiation of antineoplastic therapy.
timeFrame: Randomization up to approximately 4.5 years.
measure: Prostate Specific Antigen Response
timeFrame: Randomization up to approximately 2 years.
measure: Incidence of Adverse Events
timeFrame: Randomization up to approximately 4.5 years
measure: Time to first symptomatic skeletal event
timeFrame: Randomization up to approximately 2 years.
measure: Change from baseline in patient reported pain symptoms per Brief Pain Inventory-Short Form (BPI-SF)
timeFrame: Randomization up to approximately 4.5 years
measure: Change from baseline in health-related quality of life (HRQoL) per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
timeFrame: Randomization to approximately 4.5 years
measure: Change from baseline in social/family well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
timeFrame: Randomization up to approximately 4.5 years
measure: Change from baseline in emotional well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
timeFrame: Randomization up to approximately 4.5 years
measure: Change from baseline in functioning well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
timeFrame: Randomization up to approximately 4.5 years
measure: Change from baseline in physical well-being per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
timeFrame: Randomization to approximately 4.5 years
measure: Change from baseline in symptoms per Functional Assessment of Cancer Therapy - Prostate (FACT-P)
timeFrame: Randomization up to approximately 4.5 years
measure: Change from baseline in patient reported health status per European Quality of Life 5-Dimension 5 Level (EQ-5D-5L)
timeFrame: Randomizaton up to approximately 4.5 years
measure: Symptomatic toxicity as measured by items from the Patient-Reported Outcome CTCAE (PRO-CTCAE)
timeFrame: Randomization up to approximately 4.5 years
measure: Overall side effect burden as measured by the FACT- GP5
timeFrame: Randomization to approximately 4.5 years
measure: Time to confirmatory deterioration in patient-reported pain symptoms per BPI-SF Item 3 "worst pain in 24 hours"
timeFrame: Randomization up to approximately 4.5 years
measure: Time to definitive deterioration in patient-reported health related quality of life (HRQoL) per FACT-P
timeFrame: Randomization up to approximately 4.5 years
measure: Time to definitive deterioration in patient-reported physical well-being per FACT-P
timeFrame: Randomization up to approximately 4.5 years
measure: To evaluate the PK of PF-06821497 when dosed with enzalutamide
timeFrame: Cycle 1 (each cycle is 28 days), Day 1 to last PK draw at the end of Cycle 6, Day 1.
measure: To assess circulating tumor DNA (ctDNA) at baseline and on treatment to evaluate tumor burden.
timeFrame: Baseline up to approximately 2 years.
Other outcomes:
Locations:
city: Homewood
country: United States
facility: Urology Centers of Alabama
state: Alabama
city: Tucson
country: United States
facility: Arizona Urology Specialists- Provide ICF for Review Only
state: Arizona
city: Tucson
country: United States
facility: Arizona Urology Specialists (AUS)-Orange Grove
state: Arizona
city: Berkeley
country: United States
facility: UCSF Cancer Center Berkeley
state: California
city: Burlingame
country: United States
facility: UCSF Cancer Center Burlingame
state: California
city: San Francisco
country: United States
facility: UCSF Investigational Drug Pharmacy
state: California
city: San Francisco
country: United States
facility: UCSF Medical Center at Mission Bay
state: California
city: San Mateo
country: United States
facility: UCSF Cancer Center San Mateo
state: California
city: Santa Rosa
country: United States
facility: Sutter Santa Rosa
state: California
city: Lakewood
country: United States
facility: Colorado Clinical Research
state: Colorado
city: Bonita Springs
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Bradenton
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Cape Coral
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Naples
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Port Charlotte
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Sarasota
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Venice
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Hinsdale
country: United States
facility: Duly Health and Care
state: Illinois
city: Lisle
country: United States
facility: Duly Health And Care
state: Illinois
city: Lisle
country: United States
facility: NextStage Clinical Research-Chicago-(04)
state: Illinois
city: Westmont
country: United States
facility: Duly Health and Care
state: Illinois
city: Louisville
country: United States
facility: The University of Louisville, James Graham Brown Cancer Center
state: Kentucky
city: Louisville
country: United States
facility: University of Louisville Hospital
state: Kentucky
city: Louisville
country: United States
facility: UofL Health Medical Center Northeast
state: Kentucky
city: Topsham
country: United States
facility: New England Cancer Specialists
state: Maine
city: Westbrook
country: United States
facility: New England Cancer Specialists
state: Maine
city: Egg Harbor Township
country: United States
facility: AtlantiCare
state: New Jersey
city: Bronx
country: United States
facility: James J. Peters VA Medical Center
state: New York
city: Middletown
country: United States
facility: Circuit Clinical /Crystal Run Healthcare LLP
state: New York
city: Middletown
country: United States
facility: Circuit Clinical
state: New York
city: Monroe
country: United States
facility: Crystal Run Healthcare
state: New York
city: Salisbury
country: United States
facility: Salisbury VA Medical Center
state: North Carolina
city: Lancaster
country: United States
facility: Keystone Urology Specialists
state: Pennsylvania
city: Myrtle Beach
country: United States
facility: AUC Urologists, LLC
state: South Carolina
city: Myrtle Beach
country: United States
facility: Carolina Urologic Research Center, LLC
state: South Carolina
city: Myrtle Beach
country: United States
facility: Grand Strand Medical Center
state: South Carolina
city: Myrtle Beach
country: United States
facility: Parkway Surgery Center
state: South Carolina
city: Nashville
country: United States
facility: SCRI Oncology Partners
state: Tennessee
city: San Antonio
country: United States
facility: USA Clinical Trials
state: Texas
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
city: Seattle
country: United States
facility: Harborview Medical Center
state: Washington
city: Seattle
country: United States
facility: Fred Hutchinson Cancer Center
state: Washington
city: Seattle
country: United States
facility: University of Washington Medical Center - Montlake
state: Washington
city: Caba
country: Argentina
facility: Centro de Urología (CDU)
state: Buenos Aires
city: Capital Federal
country: Argentina
facility: Hospital Sirio Libanes
state: Buenos Aires
city: Ciudad Autónoma de Buenos Aires
country: Argentina
facility: Instituto Alexander Fleming
state: Buenos Aires
city: Mar del Plata
country: Argentina
facility: Imagenes Mdq
state: Buenos Aires
city: Mar del Plata
country: Argentina
facility: Instituto de Investigaciones Clínicas Mar del Plata
state: Buenos Aires
city: Capital
country: Argentina
facility: Centro Medico Privado CEMAIC
state: Córdoba
city: Buenos Aires
country: Argentina
facility: IMAXE
city: Buenos Aires
country: Argentina
facility: Asociación de Beneficencia Hospital Sirio Libanés
city: Buenos Aires
country: Argentina
facility: Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)
city: Auchenflower
country: Australia
facility: Icon Cancer Centre Wesley
state: Queensland
city: Clayton
country: Australia
facility: Monash Health
state: Victoria
city: Melbourne
country: Australia
facility: Peter MacCallum Cancer Centre
state: Victoria
city: Porto Alegre
country: Brazil
facility: Hospital São Lucas da PUCRS
state: RIO Grande DO SUL
city: Santo André
country: Brazil
facility: CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
state: SÃO Paulo
city: Sao Paulo
country: Brazil
facility: Hospital Alemao Oswaldo Cruz
state: SÃO Paulo
city: São José do Rio Preto
country: Brazil
facility: Hospital de Base de São José do Rio Preto
state: SÃO Paulo
city: São José do Rio Preto
country: Brazil
facility: Fundação Faculdade Regional de Medicina de São José do Rio Preto
state: SÃO Paulo
city: São Paulo
country: Brazil
facility: Instituto do Cancer Arnaldo Vieira de Carvalho
city: São Paulo
country: Brazil
facility: IBCC - Núcleo de Pesquisa e Ensino
city: Vancouver
country: Canada
facility: BC Cancer Vancouver
state: British Columbia
city: Toronto
country: Canada
facility: Sunnybrook Research Institute
state: Ontario
city: Montréal
country: Canada
facility: Centre Hospitalier de l'Université de Montréal
state: Quebec
city: Wuhu
country: China
facility: Wannan Medical College Yijishan Hospital
state: Anhui
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital Medical University
state: Beijing
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital
state: Chongqing
city: Fuzhou
country: China
facility: Fujian Medical University Union Hospital
state: Fujian
city: Fuzhou
country: China
facility: Fujian Cancer Hospital
state: Fujian
city: Lanzhou
country: China
facility: Lanzhou university second hospital
state: Gansu
city: Guangzhou
country: China
facility: Guangzhou First People's Hospital
state: Guangdong
city: Guangzhou
country: China
facility: Southern Medical University Nanfang Hospital
state: Guangdong
city: Guilin
country: China
facility: The Second Affiliated Hospital of Guilin Medical University
state: Guangxi
city: Wuhan
country: China
facility: Union Hospital Tongji Medical College Huazhong University of Science and Technology
state: Hubei
city: Changsha
country: China
facility: Hunan Cancer Hospital
state: Hunan
city: Huai'an
country: China
facility: Huai'an First People's Hospital
state: Jiangsu
city: Nanjing
country: China
facility: Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
state: Jiangsu
city: Nantong
country: China
facility: Nantong Tumor Hospital
state: Jiangsu
city: Suzhou
country: China
facility: The Second Affiliated Hospital of Soochow University
state: Jiangsu
city: Shenyang
country: China
facility: The First Hospital of China Medical University
state: Liaoning
city: Shenyang
country: China
facility: The First Hospital of China Medical University
state: Liaoning
city: Xi'an
country: China
facility: The First Affiliated Hospital of Xi'an Jiaotong University
state: Shaanxi
city: Xi'an
country: China
facility: Shaanxi Provincial People' Hospital
state: Shaanxi
city: Yantai
country: China
facility: Yantai Yuhuangding Hospital
state: Shandong
city: Shanghai
country: China
facility: Tongji Hospital of Tongji University
state: Shanghai
city: Cheng Du
country: China
facility: West China Hospital, Sichuan University
state: Sichuan
city: Hangzhou
country: China
facility: Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
state: Zhejiang
city: Jiaxing
country: China
facility: The First Hospital of Jiaxing
state: Zhejiang
city: Ningbo
country: China
facility: The first affiliated hospital of Ningbo university
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
state: Zhejiang
city: Olomouc
country: Czechia
facility: Fakultni nemocnice Olomouc
state: Olomoucký KRAJ
city: Pardubice
country: Czechia
facility: Multiscan
state: Pardubický KRAJ
city: PRague
country: Czechia
facility: Fakultni nemocnice Kralovske Vinohrady
state: Praha 10
city: Prague
country: Czechia
facility: Fakultni Thomayerova nemocnice
state: Praha 4
city: Hradec Králové
country: Czechia
facility: Nukleární Medicína
city: Pardubice
country: Czechia
facility: Radiodiagnostika Pardubice
city: Nice
country: France
facility: Centre Antoine Lacassagne
state: Alpes-maritimes
city: Nice
country: France
facility: Centre Antoine-Lacassagne
state: Alpes-maritimes
city: Strasbourg
country: France
facility: Institut de cancérologie Strasbourg Europe (ICANS)
state: Alsace
city: Brest
country: France
facility: CHRU de Brest
state: Finistère
city: Nîmes
country: France
facility: Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire
state: Gard
city: Toulouse
country: France
facility: Oncopole Claudius Regaud
state: Haute-garonne
city: Suresnes
country: France
facility: Hôpital Foch
state: Hauts-de-seine
city: Saint Grégoire
country: France
facility: Centre Hospitalier Privé Saint-Grégoire
state: Ille-et-vilaine
city: Reims
country: France
facility: Institut Jean Godinot
state: Marne
city: Lyon Cedex08
country: France
facility: Centre Leon Berard
state: Rhône-alpes
city: Pierre-Bénite
country: France
facility: Centre Hospitalier Lyon Sud
state: Rhône
city: Villejuif
country: France
facility: Gustave Roussy
state: Val-de-marne
city: Clermont-Ferrand
country: France
facility: Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne
city: Nürtingen
country: Germany
facility: Studienpraxis Urologie
state: Baden-württemberg
city: Tübingen
country: Germany
facility: Universitaetsklinikum Tuebingen
state: Baden-württemberg
city: Mettmann
country: Germany
facility: Urologie Neandertal - Praxis Mettmann
state: Nordrhein-westfalen
city: Münster
country: Germany
facility: Universitätsklinikum Münster - Albert Schweitzer Campus
state: Nordrhein-westfalen
city: Hamburg
country: Germany
facility: Universitaetsklinikum Hamburg-Eppendorf
city: Athens
country: Greece
facility: Alexandra General Hospital of Athens
state: Attikí
city: Athens
country: Greece
facility: Athens Medical Center
state: Attikí
city: Athens
country: Greece
facility: Metropolitan General Hospital
state: Attikí
city: Chaidari
country: Greece
facility: Attikon General University Hospital
state: Attikí
city: Meldola
country: Italy
facility: IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
state: Emilia-romagna
city: Roma
country: Italy
facility: Istituto Nazionale Tumori Regina Elena
state: Lazio
city: Milano
country: Italy
facility: Ospedale San Raffaele
city: Chiba-shi
country: Japan
facility: Chiba cancer center
state: Chiba
city: Kashiwa
country: Japan
facility: National Cancer Center Hospital East
state: Chiba
city: Matsuyama
country: Japan
facility: National Hospital Organization Shikoku Cancer Center
state: Ehime
city: Sapporo
country: Japan
facility: National Hospital Organization Hokkaido Cancer Center
state: Hokkaido
city: Sapporo
country: Japan
facility: Hokkaido University Hospital
state: Hokkaido
city: Kobe
country: Japan
facility: Kobe University Hospital
state: Hyogo
city: Kanazawa
country: Japan
facility: Kanazawa University Hospital
state: Ishikawa
city: Yokohama
country: Japan
facility: Yokohama City University Medical Center
state: Kanagawa
city: Yokosuka
country: Japan
facility: Yokosuka Kyosai Hospital
state: Kanagawa
city: Suita
country: Japan
facility: The University of Osaka Hospital
state: Osaka
city: Shinjuku-ku
country: Japan
facility: Keio university hospital
state: Tokyo
city: Fukuoka
country: Japan
facility: National Hospital Organization Kyushu Cancer Center
city: Kumamoto
country: Japan
facility: National Hospital Organization Kumamoto Medical Center
city: Osaka
country: Japan
facility: Osaka International Cancer Institute
city: Yamagata
country: Japan
facility: Yamagata University Hospital
city: Hwasun
country: Korea, Republic of
facility: Chonnam National University Hwasun Hospital
state: Jeonranamdo
city: Goyang-si
country: Korea, Republic of
facility: National Cancer Center
state: Kyǒnggi-do
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
state: Seoul-teukbyeolsi [seoul]
city: Seoul
country: Korea, Republic of
facility: Severance Hospital, Yonsei University Health System
state: Seoul-teukbyeolsi [seoul]
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
state: Seoul-teukbyeolsi [seoul]
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
state: Seoul-teukbyeolsi [seoul]
city: Seoul
country: Korea, Republic of
facility: Ewha Womans University Mokdong Hospital
state: Seoul-teukbyeolsi [seoul]
city: Daegu
country: Korea, Republic of
facility: Kyungpook National University Chilgok Hospital
state: Taegu-kwangyǒkshi
city: Leeuwarden
country: Netherlands
facility: Frisius Medisch Centrum
state: Fryslân
city: Nijmegen
country: Netherlands
facility: Canisius-Wilhelmina Ziekenhuis
state: Gelderland
city: Hilversum
country: Netherlands
facility: Tergooi MC
state: Noord-holland
city: Amersfoort
country: Netherlands
facility: Meander Medisch Centrum
state: Utrecht
city: Wroclaw
country: Poland
facility: 4 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ
state: Dolnośląskie
city: Torun
country: Poland
facility: MICS Centrum Medyczne Torun
state: Kujawsko-pomorskie
city: Kraków
country: Poland
facility: Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
state: Małopolskie
city: Kraków
country: Poland
facility: Szpital Specjalistyczny im. Ludwika Rydygiera w Krakowie
state: Małopolskie
city: Kosice
country: Slovakia
facility: Vychodoslovensky onkologicky ustav, a.s.
city: Martin
country: Slovakia
facility: Univerzitna nemocnica Martin, Onkologicka ambulancia
city: Presov
country: Slovakia
facility: MILAB, s.r.o., Urologicka ambulancia
city: Presov
country: Slovakia
facility: BEKY - MED, s.r.o.
city: Trnava
country: Slovakia
facility: Fakultna nemocnica Trnava
city: Port Elizabeth
country: South Africa
facility: Cancercare Langenhoven Drive Oncology Centre
state: Eastern CAPE
city: Pretoria
country: South Africa
facility: Wilgers Oncology Centre
state: Gauteng
city: George
country: South Africa
facility: TASK Eden
state: Western CAPE
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona
state: Catalunya [cataluña]
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
state: Catalunya [cataluña]
city: Madrid
country: Spain
facility: Hospital Universitario Ramón y Cajal
state: Madrid, Comunidad DE
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
state: Madrid, Comunidad DE
city: Madrid
country: Spain
facility: Hospital Universitario HM Sanchinarro
city: Manresa
country: Spain
facility: Althaia, Xarxa Assistencial Universitària de Manresa
city: València
country: Spain
facility: Hospital Universitari i Politecnic La Fe
city: Stockholm
country: Sweden
facility: Södersjukhuset
state: Stockholms LÄN [se-01]
city: Kaohsiung
country: Taiwan
facility: Kaohsiung Medical University Chung-Ho Memorial Hospital
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Tainan
country: Taiwan
facility: National Cheng Kung University Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Taoyuan
country: Taiwan
facility: Chang Gung Medical Foundation-Linkou Branch
city: İstanbul
country: Turkey
facility: Koç Üniversitesi Hastanesi
state: İ̇stanbul
city: Ankara
country: Turkey
facility: Memorial Ankara Hastanesi
city: Blackburn
country: United Kingdom
facility: Royal Blackburn Hospital
state: Blackburn WITH Darwen
city: Edinburgh
country: United Kingdom
facility: Western General Hospital
state: Midlothian
city: Glasgow
country: United Kingdom
facility: The Beatson West of Scotland Cancer Centre
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References: